Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.

Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A.

J Clin Neurosci. 2011 Jul;18(7):997-8. doi: 10.1016/j.jocn.2010.12.011. Epub 2011 May 11.

PMID:
21565508
2.

Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay.

Hayakawa S, Mori M, Okuta A, Kamegawa A, Fujiyoshi Y, Yoshiyama Y, Mitsuoka K, Ishibashi K, Sasaki S, Hattori T, Kuwabara S.

J Neuroimmunol. 2008 May 30;196(1-2):181-7. doi: 10.1016/j.jneuroim.2008.03.009. Epub 2008 May 6.

PMID:
18462810
3.

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.

Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W.

Brain. 2008 Nov;131(Pt 11):3072-80. doi: 10.1093/brain/awn240. Epub 2008 Oct 22.

4.

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T.

Neurology. 2011 Apr 12;76(15):1310-5. doi: 10.1212/WNL.0b013e3182152881.

PMID:
21482945
5.

Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4.

Kim W, Lee JE, Li XF, Kim SH, Han BG, Lee BI, Kim JK, Choi K, Kim HJ.

Mult Scler. 2012 May;18(5):578-86. doi: 10.1177/1352458511424590. Epub 2011 Sep 30.

PMID:
21965418
6.

Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Ishii N, Itoyama Y.

Tohoku J Exp Med. 2006 Dec;210(4):307-13.

7.

Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.

Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, Kieseier B, Mayatepek E, Hartung HP, Kuempfel T, Aktas O.

Mult Scler. 2013 Oct;19(11):1544-7. doi: 10.1177/1352458513498125. Epub 2013 Jul 25.

PMID:
23886825
8.

Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population.

Vaknin-Dembinsky A, Brill L, Orpaz N, Abramsky O, Karussis D.

Mult Scler. 2010 Dec;16(12):1453-7. doi: 10.1177/1352458510380416. Epub 2010 Oct 8.

PMID:
20935029
9.

Neuromyelitis optica.

Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG.

Curr Opin Neurol. 2007 Jun;20(3):255-60. Review.

PMID:
17495617
10.

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.

Palace J, Leite MI, Nairne A, Vincent A.

Arch Neurol. 2010 Aug;67(8):1016-7. doi: 10.1001/archneurol.2010.188.

PMID:
20697055
11.

Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica.

Isobe N, Yonekawa T, Matsushita T, Masaki K, Yoshimura S, Fichna J, Chen S, Furmaniak J, Smith BR, Kira J.

Neurochem Res. 2013 May;38(5):997-1001. doi: 10.1007/s11064-013-1009-0. Epub 2013 Mar 2.

PMID:
23456674
12.

Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.

Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A.

J Neurol Sci. 2013 May 15;328(1-2):77-82. doi: 10.1016/j.jns.2013.02.024. Epub 2013 Mar 21.

PMID:
23522498
13.

Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica.

Li W, Minohara M, Piao H, Matsushita T, Masaki K, Matsuoka T, Isobe N, Su JJ, Ohyagi Y, Kira J.

Mult Scler. 2009 Dec;15(12):1411-21. doi: 10.1177/1352458509348961. Epub 2009 Nov 13.

PMID:
19965522
14.

Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients.

Fazio R, Malosio ML, Lampasona V, De Feo D, Privitera D, Marnetto F, Centonze D, Ghezzi A, Comi G, Furlan R, Martino G.

Mult Scler. 2009 Oct;15(10):1153-63. doi: 10.1177/1352458509106851. Epub 2009 Aug 10.

PMID:
19667009
15.

Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission.

Wang S, Yang T, Wan J, Zhang Y, Fan Y.

Brain Behav. 2017 Mar 10;7(4):e00648. doi: 10.1002/brb3.648. eCollection 2017 Apr.

16.

Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica.

Saikali P, Cayrol R, Vincent T.

Autoimmun Rev. 2009 Dec;9(2):132-5. doi: 10.1016/j.autrev.2009.04.004. Epub 2009 Apr 21. Review.

PMID:
19389490
17.

The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan.

Wang KC, Tsai CP, Lee CL, Chen SY, Chen SJ.

Eur Neurol. 2011;65(2):99-104. doi: 10.1159/000322740. Epub 2011 Jan 27.

PMID:
21273778
18.

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y.

Brain. 2007 May;130(Pt 5):1235-43. Epub 2007 Apr 19.

PMID:
17449477
19.

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.

Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B.

Nat Clin Pract Neurol. 2008 Apr;4(4):202-14. doi: 10.1038/ncpneuro0764. Epub 2008 Mar 11. Review.

PMID:
18334978
20.

Serum-positive and -negative AQP4 antibody NMO in Chinese patients.

Long Y, Lu Z, Hu X.

Can J Neurol Sci. 2012 Mar;39(2):232-5.

PMID:
22343159

Supplemental Content

Support Center